Kearnan Welch, DO
Endocrinology, Diabetes & Metabolism · Monterey, CANPI 1720463854
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,575 of the $4,548 with a category attached, or 78.6%. 19 manufacturers reported payments, led by Novo Nordisk at 38.1% of the total. Reporting peaked in 2019 at $1,589 and has fallen 71.4% since, to $454 in 2025.
Across 73 payments — averaging $62.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Corcept Therapeutics$726
- Abbott$459
- Amgen$406
- BETA Bionics, Inc.$388
- Tandem Diabetes Care, Inc.$178
- plus $656 from 13 others
What the payments were for
- Travel & lodging$94421%
- Food & beverage$3,57579%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 10 | $1,734 |
| Corcept Therapeutics | 8 | $726 |
| Abbott | 21 | $459 |
| Amgen | 9 | $406 |
| BETA Bionics, Inc. | 4 | $388 |
| Tandem Diabetes Care, Inc. | 2 | $178 |
| Lilly USA, LLC | 3 | $158 |
| AbbVie | 1 | $116 |
| Radius Health, Inc. | 2 | $64 |
| Dexcom, Inc. | 3 | $63 |
| Insulet Corporation | 2 | $53 |
| AstraZeneca | 1 | $34 |
| Sanofi-aventis U.S. LLC | 1 | $31 |
| Bigfoot Biomedical Inc | 1 | $30 |
| Sequel Med Tech, LLC | 1 | $28 |
| Ascendis Pharma Endocrinology Inc | 1 | $24 |
| Bayer | 1 | $22 |
| Boehringer Ingelheim | 1 | $19 |
| Medtronic | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$1,053
- Korlym$333
- t:slim X2 insulin pump$132
- RYBELSUS$125
- VRAYLAR$116
- MOUNJARO$109
How this compares
$4,548 in reported general payments places this provider in the 70th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 364 | $469,612 |
| OzempicSemaglutide | 180 | $251,774 |
| JardianceEmpagliflozin | 204 | $224,794 |
| TrulicityDulaglutide | 104 | $171,419 |
| RybelsusSemaglutide | 31 | $45,603 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 29 | $40,309 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 27 | $37,576 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 56 | $26,666 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 25 | $22,632 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $17,924 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $16,865 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 145 | $15,789 |
| WegovySemaglutide | 11 | $14,842 |
| Testosterone | 43 | $11,429 |
| Gvoke Hypopen 2-PackGlucagon | 16 | $9,886 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $158 | $642,807480 claims |
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Wegovy | $1,734 | $349,794249 claims |
| Boehringer IngelheimJardiance | $19 | $224,794204 claims |
| AbbVieSynthroid | $116 | $5,48353 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Monterey
- James ChuMonterey$639K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.